-
Argentine scientists lay first traps in hantavirus hunt
-
Star of Rome's 'sexy priest' calendar admits: 'I was never a priest'
-
Harry Styles fans to splash over £1 bn on London concerts: Barclays
-
Bolivia protest sees violent clashes, looting in La Paz
-
Trump says held off on new Iran attack, upbeat for agreement
-
Los Angeles World Cup workers vow strike over ICE guarantees
-
Three killed in San Diego mosque shooting, two attackers dead
-
US to screen for Ebola at airports, one American in DR Congo infected
-
Aussie Scott officially set for 100th straight major at US Open
-
Pep Guardiola to leave Man City at end of the season - reports
-
Neymar back in Brazil squad for fourth World Cup
-
Arsenal on the brink of Premier League title after nervy Burnley win
-
Oil rises, global stocks mixed as markets track Iran developments
-
World Cup winner Pavard confirms Marseille exit
-
Trump says holding off on new Iran attack
-
Cuba warns of 'bloodbath' if US attacks; Washington adds sanctions
-
Trump says delaying Iran attack at request of Gulf leaders
-
Cuba warns of 'bloodbath' if US attacks and Washington issues sanctions
-
After mayor's murder, Mexico battles to bring peace
-
Trump admin creates $1.7 bln fund to compensate allies prosecuted under Biden
-
Pelicans name Mosley as coach, two weeks after Magic firing
-
Hyderabad qualify for IPL play-offs along with Gujarat
-
'Girl in the River Main' identified 25 years on, father arrested
-
Musk loses blockbuster OpenAI suit as jury says too late
-
SNC Scandic Coin and Biconomy: Regulated real-world assets meet global trading infrastructure
-
Judge allows gun as evidence in Mangione healthcare exec murder trial
-
First attack on Arab nuclear site sends warning to Gulf, US
-
Oil rises, bond yields weigh on stocks
-
Hormuz tanker traffic edges higher after wartime low
-
Andalusia setback highlights weakness of Spain's ruling Socialists
-
India's Adani to pay $275 mn settlement to US over alleged Iran sanctions violations
-
Middle East tourism pain is Europe's gain
-
UK Labour leadership hopeful reopens Brexit debate
-
PSG's Dembele has treatment for leg issue before Champions League final
-
Spurs must play with 'courage' to seal safety: De Zerbi
-
Hantavirus-hit cruise ship ends deadly voyage
-
Champagne start in Reims for 2028 Tour de France
-
Dogs allowed on new Brigitte Bardot beach in glitzy Cannes
-
Oil prices dip on report of US sanctions relief for Iran during talks
-
Croatia names Modric-led World Cup squad
-
Iran World Cup squad lands in south Turkey for training
-
Mushfiqur ton leaves Pakistan needing record run chase to beat Bangladesh
-
Transport protests hit Kenya over rising fuel prices
-
Ex-Google exec takes reins at under-fire BBC
-
France unveils architects to transform Louvre
-
'Mesmeric' movie on secret lives of Nigeria's rich wows Cannes
-
Ex-Google man takes reins at under-fire BBC
-
Swatch blames shopping centres for 'problems' with star product launch
-
Carvajal to leave Real Madrid at end of season
-
Stocks drop, oil climbs after fresh Trump warning to Iran
US FDA says Pfizer Covid vaccine effective in kids under five
The US Food and Drug Administration (FDA) has said the Pfizer Covid vaccine is safe and effective in children under five, ahead of a meeting to weigh its authorization later this week.
Children under five are the only age group not yet eligible for vaccination in the United States and most countries, a pressing need since rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age," the FDA said in a document posted on its website Sunday.
The agency has called a meeting of experts on June 15 to decide whether to recommend the Pfizer vaccine, given as three shots to children aged six months through four years, as well as the Moderna vaccine, given as two shots to children aged six months through five years.
Pfizer's first two shots are given three weeks apart, then the third is given eight weeks after the second. They are all dosed at three micrograms, as opposed to 30 micrograms the company gives older ages.
Both Pfizer and Moderna had previously posted their results, but the FDA then had to review the data in detail and carry out its own evaluation. It posted a favorable analysis about Moderna on Friday.
Its comments towards Pfizer also appear favorable, based on the levels of infection-blocking antibodies it evoked in trial participants, and a similar side-effect profile to higher age groups. The trial population was around 4,500 children.
A preliminary estimate placed vaccine efficacy at 80.3 percent, but the FDA noted this was based on very few positive cases -- just 10, as opposed to the 21 sought for a more accurate figure.
There are nearly 20 million US children aged four years and under, or six percent of the population. If, as expected, the FDA-appointed experts recommend the two shots, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
E.AbuRizq--SF-PST